Loading stock data…
argenx SE (ARGX)
$899.42+12.24 (+1.38%)
Market OpenUpdated 2:07 PM EDT
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
argenx SE in the Healthcare sector is trading at $899.42 with a market capitalization of $54.8B. Wall Street consensus targets $1,041.71 (23 analysts), implying a +15.8% move over the next 12 months. The stock is currently near its 52-week high of $934.62, remaining 10.3% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +15.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.30B↑ | $1.29B↑ | $1.13B↑ | $947.96M↑ | $790.00M |
| Gross Profit | $1.18B↑ | $1.14B↑ | $1.02B↑ | $837.21M↑ | $709.00M |
| Operating Income | $394.00M↑ | $359.56M↑ | $349.97M↑ | $203.84M↑ | $139.00M |
| Net Income | $366.00M↓ | $532.95M↑ | $344.26M↑ | $245.36M↑ | $169.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and imm...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$54.79B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
20.33%
Volume
Today's trading volume
155,116
Recent News
European Equities Traded in US as ADRs Rise in Thursday Trading
European equities traded in the US as American depositary receipts rose late Thursday morning with t
Can Argenx Retake Its Record High — And A Buy Point — On A New Vyvgart Strategy?
Argenx stock wavered Wednesday, briefly bumping above its 21-day line, as investors digested its myositis-focused R&D Day.
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
European equities traded in the US as American depositary receipts were sharply higher late Wednesda
argenx Eyes More VYVGART Growth as Pipeline Catalysts Near
Executives at argenex (NASDAQ:ARGX) told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, while also pointing to a busy slate of pipeline readouts in the
Assessing argenx (ENXTBR:ARGX) Valuation After Strong Recent Share Price Momentum
Short term performance snapshot argenx (ENXTBR:ARGX) has drawn investor interest after recent trading, with the stock last closing at €763. Over the past week it returned 9.7%, with roughly 10.4% in the past month. Looking a bit further back, the stock shows a return of about 23.9% over the past 3 months and 5.4% year to date, while the 1 year total return stands at 50.7%. See our latest analysis for argenx. The recent 7 day share price return of 9.7% at €763 sits on top of a 3 month share...